140 related articles for article (PubMed ID: 34262681)
1. Improved clinical outcomes of tocilizumab
Zongfei J; Lijuan Z; Ying S; Dongmei L; Sifan W; Xiufang K; Lingying M; Yun L; Lili M; Huiyong C; Lindi J
Ther Adv Chronic Dis; 2021; 12():20406223211028776. PubMed ID: 34262681
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study.
Luo X; Peng Y; Zhang P; Li J; Liu Z; Lu H; Zhang X; Zeng X; Zhang F; Fei Y; Zhang W
Front Med (Lausanne); 2020; 7():253. PubMed ID: 32733900
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Liu Y; Zhang Y; Bian W; Fu J; Sun X; Chen D; Chen J; Zhao X; Li Y; Zhang W; Li Z
Clin Rheumatol; 2020 Feb; 39(2):491-497. PubMed ID: 31848912
[TBL] [Abstract][Full Text] [Related]
4. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
[TBL] [Abstract][Full Text] [Related]
5. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Dong C; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Semin Arthritis Rheum; 2020 Dec; 50(6):1513-1520. PubMed ID: 32113839
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
7. Correlation between serologic parameters and disease activity of IgG4-related disease: Differences between patients with normal and elevated serum IgG4 concentrations.
Kwon OC; Park MC; Kim YG
Front Immunol; 2022; 13():1020459. PubMed ID: 36311699
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Patterns and Predictors of the Functional Restoration of Immunoglobulin G4-Related Kidney Disease: A Chinese Single-Center Cohort Study.
Su T; Wang H; Wang S; Yang L
Front Med (Lausanne); 2021; 8():736098. PubMed ID: 34692728
[No Abstract] [Full Text] [Related]
10. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of leflunomide
Ying S; Xiaomeng C; Xiaomin D; Jiang L; Peng L; Lili M; Rongyi C; Zongfei J; Huiyong C; Lindi J
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20930114. PubMed ID: 32536986
[TBL] [Abstract][Full Text] [Related]
12. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain.
Quero M; Draibe J; Solanich X; Rama I; Gomà M; Martínez-Valenzuela L; Fulladosa X; Cruzado JM; Torras J
Clin Kidney J; 2019 Dec; 12(6):829-835. PubMed ID: 31807295
[TBL] [Abstract][Full Text] [Related]
14. Revealing the distinct clinical patterns and relapse risk factors in seronegative IgG4-RD patients: A retrospective cohort study over a decade.
Peng Y; Wang M; Sun R; Nie Y; Zhang N; He X; Sun B; Peng L; Fei Y; Zhou J; Li M; Zhang W
J Intern Med; 2024 Jun; ():. PubMed ID: 38924246
[TBL] [Abstract][Full Text] [Related]
15. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease.
Berti A; Della-Torre E; Gallivanone F; Canevari C; Milani R; Lanzillotta M; Campochiaro C; Ramirez GA; Bozzalla Cassione E; Bozzolo E; Pedica F; Castiglioni I; Arcidiacono PG; Balzano G; Falconi M; Gianolli L; Dagna L
Rheumatology (Oxford); 2017 Dec; 56(12):2084-2092. PubMed ID: 28977663
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study.
Dai X; Cui X; Sun Y; Ma L; Jiang L
Ther Adv Chronic Dis; 2020; 11():2040622320922019. PubMed ID: 32551033
[TBL] [Abstract][Full Text] [Related]
18. A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab.
Backhus J; Neumann C; Perkhofer L; Schulte LA; Mayer B; Seufferlein T; Müller M; Kleger A
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807051
[TBL] [Abstract][Full Text] [Related]
19. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
[TBL] [Abstract][Full Text] [Related]
20. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
